Practical considerations when treating chronic hepatitis E in solid organ transplant recipients.

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis E virus (HEV) poses a risk for chronic infection, particularly in immunosuppressed individuals.
• Antiviral treatment with ribavirin is recognized for chronic HEV, but specific guidance for transplant patients is limited.
• Managing HEV in solid organ transplant recipients requires careful consideration of drug interactions and monitoring.

Purpose of the Study:

• To describe a practical, real-world strategy for utilizing ribavirin in a solid organ transplant recipient with chronic Hepatitis E virus infection.
• To outline key considerations for ribavirin therapy, including drug interactions, dosage adjustments, and monitoring parameters in this patient population.

Main Methods:

• Retrospective case review of a solid organ transplant recipient with chronic HEV infection.
• Detailed documentation of ribavirin treatment regimen, including initiation, titration, and management of potential adverse events.
• Monitoring of viral load, liver function tests, and drug-drug interactions throughout the treatment course.

Main Results:

• Successful treatment of chronic HEV infection with ribavirin in a solid organ transplant recipient.
• Demonstration of a feasible approach to managing ribavirin therapy, including dose adjustments and monitoring, in this complex patient group.
• Identification of key factors contributing to treatment success and tolerance.

Conclusions:

• Ribavirin can be an effective treatment option for chronic Hepatitis E virus in solid organ transplant recipients.
• A structured, real-world approach is crucial for optimizing ribavirin therapy, managing drug interactions, and ensuring patient safety.
• Further research into standardized protocols for HEV treatment in transplant populations is warranted.